These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32367460)

  • 1. Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors.
    Wang C; Mu Z; Ye Z; Zhang Z; Abu-Khalaf MM; Silver DP; Palazzo JP; Jagannathan G; Fellin FM; Bhattacharya S; Jaslow RJ; Tsangaris TN; Berger A; Neupane M; Cescon TP; Lopez A; Yao K; Chong W; Lu B; Myers RE; Hou L; Wei Q; Li B; Cristofanilli M; Yang H
    Breast Cancer Res Treat; 2020 Jun; 181(3):679-689. PubMed ID: 32367460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nomogram for predicting the HER2 status of circulating tumor cells and survival analysis in HER2-negative breast cancer.
    Yang Y; Li L; Tian W; Qiao Z; Qin Q; Su L; Li P; Chen W; Zhao H
    Front Oncol; 2022; 12():943800. PubMed ID: 36620609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.
    Lee CK; Davies L; Gebski VJ; Lord SJ; Di Leo A; Johnston S; Geyer C; Cameron D; Press MF; Ellis C; Loi S; Marschner I; Simes J; de Souza P
    J Clin Oncol; 2016 Mar; 34(9):936-44. PubMed ID: 26811533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
    Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z
    BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker.
    Liu Y; Liu Q; Wang T; Bian L; Zhang S; Hu H; Li S; Hu Z; Wu S; Liu B; Jiang Z
    BMC Cancer; 2013 Apr; 13():202. PubMed ID: 23617715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
    Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
    BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer.
    Prat A; Carey LA; Adamo B; Vidal M; Tabernero J; Cortés J; Parker JS; Perou CM; Baselga J
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25139534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance.
    Li Y; Zhang X; Liu D; Gong J; Wang DD; Li S; Peng Z; Li Y; Wang X; Lin PP; Li M; Shen L
    Clin Cancer Res; 2018 Nov; 24(21):5261-5271. PubMed ID: 30012565
    [No Abstract]   [Full Text] [Related]  

  • 9. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
    Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
    Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
    Banys-Paluchowski M; Witzel I; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer EF; Aktas B; Kasimir-Bauer S; Pantel K; Fehm T; Müller V
    Anticancer Res; 2017 Jun; 37(6):3117-3128. PubMed ID: 28551653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Evaluation of Risk Stratification and Clinical Outcomes for Patients with Advanced Breast Cancer through Combined Monitoring of Baseline Circulating Tumor Cells and DNA.
    Zhang Q; Cai Z; Gerratana L; Davis AA; D'Amico P; Chawla A; Jacob S; Zhang Y; Jiao J; Qin W; Reduzzi C; Flaum L; Shah A; Gradishar WJ
    Clin Cancer Res; 2024 Aug; 30(16):3470-3480. PubMed ID: 38829582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HER2-targeted therapy influences CTC status in metastatic breast cancer.
    Deutsch TM; Riethdorf S; Fremd C; Feisst M; Nees J; Fischer C; Hartkopf AD; Pantel K; Trumpp A; Schütz F; Schneeweiss A; Wallwiener M
    Breast Cancer Res Treat; 2020 Jul; 182(1):127-136. PubMed ID: 32436146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial.
    Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W;
    BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prognostic Value of HER2-Positive Circulating Tumor Cells in Breast Cancer Patients: A Systematic Review and Meta-Analysis.
    Wang CH; Chang CJ; Yeh KY; Chang PH; Huang JS
    Clin Breast Cancer; 2017 Aug; 17(5):341-349. PubMed ID: 28347604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Value of serum human epithelial growth factor receptor 2 extracellular domain and circulating tumor cells in evaluating therapeutic response in advanced gastric cancer].
    Li Y; Peng Z; Zhang X; Gong J; Shen L
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Nov; 20(11):1293-1299. PubMed ID: 29178102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
    Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
    Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot Study on the Utility of Circulating HER2/Neu Levels in the Serum of Breast Cancer Patients.
    Morgan S; Amemiya Y; Slodkowska E; Lu FI; Parra-Herran C; Nofech-Mozes S; Trudeau M; Olkhov-Mitsel E; Seth A; Hanna WM
    Anticancer Res; 2019 Oct; 39(10):5345-5352. PubMed ID: 31570428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer.
    Stefanovic S; Deutsch TM; Riethdorf S; Fischer C; Hartkopf A; Sinn P; Feisst M; Pantel K; Golatta M; Brucker SY; Sütterlin M; Schneeweiss A; Wallwiener M
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
    Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
    Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31.
    Gelmon KA; Boyle FM; Kaufman B; Huntsman DG; Manikhas A; Di Leo A; Martin M; Schwartzberg LS; Lemieux J; Aparicio S; Shepherd LE; Dent S; Ellard SL; Tonkin K; Pritchard KI; Whelan TJ; Nomikos D; Nusch A; Coleman RE; Mukai H; Tjulandin S; Khasanov R; Rizel S; Connor AP; Santillana SL; Chapman JA; Parulekar WR
    J Clin Oncol; 2015 May; 33(14):1574-83. PubMed ID: 25779558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.